Literature DB >> 31463118

Expression levels of paraoxonase-1 in aortic valve tissue are associated with the progression of calcific aortic valve stenosis.

Jian Song1, Qiang Zheng1, Xiaochun Ma1, Qian Zhang1, Zhenqiang Xu1, Chengwei Zou1, Zhengjun Wang1.   

Abstract

BACKGROUND: Paraoxonase-1 (PON1) participates in several vital steps of lipid metabolism, which is associated with calcific aortic valve stenosis (CAVS). Although a few studies have suggested that PON1 in blood could inhibit aortic valve calcification, they did not provide detailed descriptions. In this study, we hypothesized that PON1 is expressed in the aortic valve and that the PON1 level is related to the severity of CAVS.
METHODS: A total of 118 consecutive patients with CAVS were enrolled in the study; 35 individuals without aortic valve calcification were included in the control group. Aortic valve tissue was obtained from postoperative pathologic specimens. PON1 was detected qualitatively using immunohistochemistry and quantitatively using an enzyme-linked immunosorbent assay. The severity of aortic stenosis was evaluated using echocardiography.
RESULTS: We detected PON1 in the aortic valve and noticed that the PON1 level was significantly lower in the case group than in the control group (P<0.001). Furthermore, we found no significant difference between the mild and moderate stenosis groups (P=0.395). However, the PON1 levels were obviously higher in both the mild and moderate stenosis groups than in the severe stenosis group (both P<0.001). We also detected a significant negative correlation between PON1 level and the maximum aortic valve gradient in the case group.
CONCLUSIONS: We detected PON1 in the aortic valve for the first time, and our results suggest that the PON1 level in aortic valve tissue decreases with increasing severity of aortic valve stenosis.

Entities:  

Keywords:  Paraoxonase-1 (PON1); aortic valve calcification; stenosis

Year:  2019        PMID: 31463118      PMCID: PMC6688040          DOI: 10.21037/jtd.2019.07.41

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  34 in total

1.  Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome.

Authors:  Bharti Mackness; Rozenn Quarck; Wim Verreth; Mike Mackness; Paul Holvoet
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-04-20       Impact factor: 8.311

2.  Paraoxonase activity might be predictive of the severity of aortic valve stenosis.

Authors:  Goksel Cagirci; Serkan Cay; Ozlem Karakurt; Tahir Durmaz; Nuray Yazihan; Aytun Canga; Cengiz Aydin; Sadik Acikel; Harun Kilic; Serkan Topaloglu; Dursun Aras; Ahmet Duran Demir; Ramazan Akdemir
Journal:  J Heart Valve Dis       Date:  2010-07

3.  Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis.

Authors:  H Jakubowski; L Zhang; A Bardeguez; A Aviv
Journal:  Circ Res       Date:  2000-07-07       Impact factor: 17.367

Review 4.  The three-gene paraoxonase family: physiologic roles, actions and regulation.

Authors:  Louis-Philippe Précourt; Devendra Amre; Marie-Claude Denis; Jean-Claude Lavoie; Edgard Delvin; Ernest Seidman; Emile Levy
Journal:  Atherosclerosis       Date:  2010-10-12       Impact factor: 5.162

5.  Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.

Authors:  Tamali Bhattacharyya; Stephen J Nicholls; Eric J Topol; Renliang Zhang; Xia Yang; David Schmitt; Xiaoming Fu; Mingyuan Shao; Danielle M Brennan; Stephen G Ellis; Marie-Luise Brennan; Hooman Allayee; Aldons J Lusis; Stanley L Hazen
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

Review 6.  Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development.

Authors:  Michael Aviram; Mira Rosenblat
Journal:  Free Radic Biol Med       Date:  2004-11-01       Impact factor: 7.376

Review 7.  Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis?

Authors:  Srinivasa T Reddy; Asokan Devarajan; Noam Bourquard; Diana Shih; Alan M Fogelman
Journal:  Curr Opin Lipidol       Date:  2008-08       Impact factor: 4.776

Review 8.  The paraoxonases: role in human diseases and methodological difficulties in measurement.

Authors:  Jordi Camps; Judit Marsillach; Jorge Joven
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

9.  Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis.

Authors:  C Côté; P Pibarot; J-P Després; D Mohty; A Cartier; B J Arsenault; C Couture; P Mathieu
Journal:  Heart       Date:  2007-10-11       Impact factor: 5.994

10.  Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides.

Authors:  M Mastorikou; B Mackness; Y Liu; M Mackness
Journal:  Diabet Med       Date:  2008-09       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.